Be ready for the possible transition from RRMS to SPMS by understanding new symptoms, treatment options, and what to discuss ...

Women with multiple sclerosis, particularly after menopause, experience a higher risk of relapse-independent worsening, ...

Once-yearly infusions of rituximab are as effective as twice-yearly dosing for sustained control of MS in a new phase 3 trial ...

Most people with relapsing MS who were treated with Briumvi for six years did not have confirmed disability progression, a ...

Most relapsing MS patients on Mavenclad did not have confirmed disability progression for at least four years, new Phase 4 ...

Please provide your email address to receive an email when new articles are posted on . Permanent discontinuation due to treatment-emergent adverse events occurred in 12% and 10.6% of treatment groups ...

Ocrelizumab is noninferior to fingolimod, demonstrating efficacy and safety in children and adolescents with ...

Please provide your email address to receive an email when new articles are posted on . Researchers analyzed data from 73 persons in the VISIONARY-MS trial treated with an oral suspension of gold ...

Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...

An experimental stem cell therapy proved effective and safe in patients with a relapsing form of multiple sclerosis (MS), an autoimmune disease that affects the central nervous system, new research ...

B-cell therapy for multiple sclerosis (MS) was first approved in 2017, after the anti-CD20 agent ocrelizumab (Ocrevus) demonstrated its ability to strongly suppress the acute inflammatory activity and ...

Frexalimab, an investigational second-generation CD40 ligand (CD40L) inhibitor, led to fewer new gadolinium-enhancing T1-weighted lesions in relapsing multiple sclerosis (MS), a phase II trial showed.